Ondansetron
- Generic Name
- Ondansetron
- Brand Names
- Zofran, Zuplenz
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19N3O
- CAS Number
- 99614-02-5
- Unique Ingredient Identifier
- 4AF302ESOS
- Background
A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
...
- Indication
In the adult patient population:
i) orally administered ondansetron tablets and orally disintegrating tablets (ODT) are indicated for:
- the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including high dose (ie. greater than or equal to 50 mg/m2) cisplatin therapy, and radiotherapy, and
...
- Associated Conditions
- Chemotherapy-Induced Nausea and Vomiting, Cholestatic pruritus, Post Operative Nausea and Vomiting (PONV), Radiation-Induced Nausea and Vomiting, Uremic Pruritus, Severe Hyperemesis gravidarum
- Associated Therapies
- -
BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron
- Conditions
- Interventions
- First Posted Date
- 2019-11-05
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 90
- Registration Number
- NCT04150614
- Locations
- 🇺🇸
University of Illinois Cancer Center, Chicago, Illinois, United States
Hemodynamic Protection of Preoperative Ondansetron 15 Minutes Before Spinal Anaesthesia in Caesarean Section
- Conditions
- Interventions
- First Posted Date
- 2019-10-25
- Last Posted Date
- 2019-10-25
- Lead Sponsor
- University of Jordan
- Target Recruit Count
- 151
- Registration Number
- NCT04140058
- Locations
- 🇯🇴
Jordan University Hospital, Amman, Jordan
Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran
- First Posted Date
- 2019-06-04
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- AMAG Pharmaceuticals, Inc.
- Target Recruit Count
- 228
- Registration Number
- NCT03973047
- Locations
- 🇺🇸
ICON Early Phase Serrvices, LLC, San Antonio, Texas, United States
Cisplatin Disposition and Kidney Injury
- Conditions
- Interventions
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 72
- Registration Number
- NCT03817970
- Locations
- 🇺🇸
UCHealth-Metro Denver, Denver, Colorado, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Validating the Effect og Ondansetron and Mirtazapine in Treating Hyperemesis Gravidarum
- Conditions
- Interventions
- First Posted Date
- 2018-12-24
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Nordsjaellands Hospital
- Target Recruit Count
- 58
- Registration Number
- NCT03785691
- Locations
- 🇩🇰
Department of Gynaecology and Obstetrics, Aarhus University Hospital, Aarhus, Denmark
🇩🇰Department of Gynaecology and Obstetrics, Rigshospitalet, Copenhagen, Denmark
🇩🇰Department of Gynaecology and Obstetrics, Herlev Hospital, Herlev, Denmark
Effects of Intraoperative Dexamethasone and Ondansetron on Postoperative Nausea and Vomiting in Microvascular Decompression Surgery
- Conditions
- Interventions
- First Posted Date
- 2018-09-26
- Last Posted Date
- 2018-09-26
- Lead Sponsor
- Khon Kaen University
- Target Recruit Count
- 54
- Registration Number
- NCT03685032
- Locations
- 🇹🇭
Khon Kaen University, Khon Kaen, Thailand
Conscious Sedation Efficacy of the MKO Melt (Midazolam, Ketamine, Ondansetron)
- Conditions
- Interventions
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Avanti Anesthesia
- Target Recruit Count
- 651
- Registration Number
- NCT03653520
- Locations
- 🇺🇸
Memorial Hermann Kirby Glen Surgery Center, Houston, Texas, United States
Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.
- Conditions
- Interventions
- First Posted Date
- 2018-07-30
- Last Posted Date
- 2018-07-30
- Lead Sponsor
- Instituto Nacional de Cancerologia de Mexico
- Target Recruit Count
- 560
- Registration Number
- NCT03606369
- Locations
- 🇲🇽
Instituto Nacional de Cancerología, Mexico City, Mexico
Noninvasive Markers of Functional Nausea in Children
- Conditions
- Interventions
- First Posted Date
- 2018-07-20
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 130
- Registration Number
- NCT03593811
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Study of APD421 With and Without Ondansetron
- Conditions
- Interventions
- First Posted Date
- 2018-07-11
- Last Posted Date
- 2018-10-01
- Lead Sponsor
- Acacia Pharma Ltd
- Target Recruit Count
- 30
- Registration Number
- NCT03583489
- Locations
- 🇬🇧
Early Phase Clinical Unit, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.